Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

11 months ago 48
ARTICLE AD BOX
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.
Read Entire Article
  1. Homepage
  2. Finance
  3. Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

Related

UnitedHealth’s stock falls further after saying it expects revenue to decline in 2026

UnitedHealth’s stock falls further after saying it expects r...

38 minutes ago 0
‘Luxury-phobia’ is turning the Chinese away from conspicuous consumption and toward ‘local hero’ domestic brands

‘Luxury-phobia’ is turning the Chinese away from conspicuous...

1 hour ago 0
Where Tech Leaders and Students Really Think AI Is Going

Where Tech Leaders and Students Really Think AI Is Going

1 hour ago 1

Trending

Popular

Can Pidcock win big & why did it end at Ineos?

Can Pidcock win big & why did it end at Ineos?

10 months ago 499
‘I didn’t want to spend time with my children. I was just going through the motions’: the pain of parental burnout

‘I didn’t want to spend time with my children. I was just go...

11 months ago 458
‘Slanted’ Review: Extreme Makeover Satire Critiques Lopsided Beauty Standards Through Asian Eyes

‘Slanted’ Review: Extreme Makeover Satire Critiques Lopsided...

10 months ago 436
Netflix scuttles plans to add six previously announced games to its service

Netflix scuttles plans to add six previously announced games...

11 months ago 392
OpenAI co-founder John Schulman has left Anthropic after less than a year

OpenAI co-founder John Schulman has left Anthropic after les...

11 months ago 346
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexa News 2026. All rights are reserved